CRE Management Guideline

About This CRE Management Guide

The CRE management guide is an interactive decision support tool designed for infectious disease specialists, critical care teams, pharmacists, and infection preventionists managing carbapenem-resistant Enterobacterales (CRE) cases. With mortality rates often exceeding 40% in invasive infections, timely and accurate management is crucial. This CRE management guide incorporates the most recent IDSA 2024 guidance, emphasizing susceptibility-driven therapy, source control, and antimicrobial stewardship to combat rising resistance. It includes carbapenemase type selection (KPC, NDM, OXA-48-like) for refined recommendations, promoting novel beta-lactam/beta-lactamase inhibitors as first-line when active.

The CRE management guide supports clinicians in high-burden settings by providing clear hierarchies for colonization versus infection, while stressing the importance of local epidemiology and infectious diseases consultation.

How to Use This CRE Management Guide

1. Select patient status (colonization or infection).
2. For infections, choose primary site and carbapenemase type.
3. View tailored recommendations instantly.
4. Use Key Knowledge Points for rapid reference.
5. Always confirm with susceptibility results, local protocols, and specialist input.

Clinical Interpretation & Limitations

Interpretation: Therapy is carbapenemase-directed. For KPC, ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam are all active. For OXA-48-like, ceftazidime-avibactam is preferred and cefiderocol is the alternative — meropenem-vaborbactam and imipenem-relebactam are not reliable against OXA-48. For NDM/metallo-β-lactamase producers, use ceftazidime-avibactam + aztreonam, cefiderocol, or aztreonam-avibactam. Monotherapy with a single active β-lactam is preferred for susceptible isolates per IDSA 2024; routine addition of a second agent adds toxicity without proven benefit (the CAZ-AVI + aztreonam pairing is the exception, used to restore activity against metallo-β-lactamases). Duration: 7-14 days for uncomplicated infection, longer for complex or undrained sources. Monitor toxicity closely.

Limitations: This CRE management guide offers general evidence-based suggestions and does not replace clinical judgment or real-time susceptibility data. Doses are baseline—renal dosing adjustments are required.

Frequently Asked Questions (FAQ)

1. What defines CRE in this CRE management guide?

CRE are Enterobacterales resistant to any carbapenem or producing a carbapenemase (e.g., KPC, NDM, OXA-48).

2. Is combination therapy always required?

No—IDSA 2024 prefers monotherapy for susceptible CRE to minimize toxicity; combinations for severe or resistant cases.

3. How does carbapenemase type affect therapy?

KPC: ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-relebactam. OXA-48-like: ceftazidime-avibactam preferred, with cefiderocol as the alternative (vaborbactam and relebactam do not cover OXA-48). NDM/metallo-β-lactamase: ceftazidime-avibactam + aztreonam, cefiderocol, or aztreonam-avibactam.

4. Is inhaled colistin recommended for CRE pneumonia?

Not routinely—current IDSA guidance does not endorse adjunctive inhaled antibiotics for CRE pneumonia due to limited evidence.

5. How should renal impairment be handled?

All recommended agents require dose adjustment in renal impairment. Refer to our Antibiotic Dosing Guide for precise adjustments.

6. When to consult ID specialists?

Always for confirmed CRE infections, per CRE management guide recommendations.

Related Calculators

• Empiric Antibiotic Selector
• COVID-19 Treatment Guideline
• Pneumonia Treatment Guideline